Estrogen receptor-beta expression in hereditary breast cancer.

[1]  T. Walsh,et al.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.

[2]  J. Gustafsson,et al.  Estrogen receptor β acts as a dominant regulator of estrogen signaling , 2000, Oncogene.

[3]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Sng,et al.  Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M. Erdos,et al.  Role of direct interaction in BRCA1 inhibition of estrogen receptor activity , 2001, Oncogene.

[6]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[7]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[8]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[9]  R. Laucirica,et al.  Estrogen receptor beta expression in invasive breast cancer. , 2001, Human pathology.

[10]  A Borg,et al.  Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes , 1998, Cancer.

[11]  D. McDonnell,et al.  The Estrogen Receptor ␤-isoform (er␤) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .